{"id":"https://openalex.org/W7225758633","doi":"https://doi.org/10.3390/biomedicines14112591","title":"A Bioavailability-Enhanced Nobiletin Formulation Potentiates the Antitumor Efficacy of DM1 and a DM1-Based Antibody\u2013Drug Conjugate","display_name":"A Bioavailability-Enhanced Nobiletin Formulation Potentiates the Antitumor Efficacy of DM1 and a DM1-Based Antibody\u2013Drug Conjugate","publication_year":2026,"publication_date":"2026-11-10","ids":{"openalex":"https://openalex.org/W7225758633","doi":"https://doi.org/10.3390/biomedicines14112591"},"language":"en","primary_location":{"id":"doi:10.3390/biomedicines14112591","doi":"https://doi.org/10.3390/biomedicines14112591","is_oa":true,"landing_page_url":"https://doi.org/10.3390/biomedicines14112591","pdf_url":null,"source":{"id":"https://openalex.org/S2737005842","display_name":"Biomedicines","issn_l":"2227-9059","issn":["2227-9059"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310310987","host_organization_name":"Multidisciplinary Digital Publishing Institute","host_organization_lineage":["https://openalex.org/P4310310987"],"host_organization_lineage_names":["Multidisciplinary Digital Publishing Institute"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biomedicines","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.3390/biomedicines14112591","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5161378276","display_name":"Tomoya Masuoka","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I158123994","display_name":"Toyo University","ror":"https://ror.org/059d6yn51","country_code":"JP","type":"education","lineage":["https://openalex.org/I158123994"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tomoya Masuoka","raw_affiliation_strings":["Department of Nutrition Sciences, Graduate School of Health and Sports Sciences, Toyo University, Tokyo 115-8650, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Nutrition Sciences, Graduate School of Health and Sports Sciences, Toyo University, Tokyo 115-8650, Japan","institution_ids":["https://openalex.org/I158123994"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047007335","display_name":"Takumi Iwasawa","orcid":"https://orcid.org/0009-0008-9278-6464","observed_orcids":["https://orcid.org/0009-0008-9278-6464"]},"institutions":[{"id":"https://openalex.org/I158123994","display_name":"Toyo University","ror":"https://ror.org/059d6yn51","country_code":"JP","type":"education","lineage":["https://openalex.org/I158123994"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Takumi Iwasawa","raw_affiliation_strings":["Institute of Life Innovation Studies, Toyo University, Tokyo 115-8650, Japan"],"raw_orcid":"https://orcid.org/0009-0008-9278-6464","affiliations":[{"raw_affiliation_string":"Institute of Life Innovation Studies, Toyo University, Tokyo 115-8650, Japan","institution_ids":["https://openalex.org/I158123994"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044295623","display_name":"Masazumi Iwashita","orcid":"https://orcid.org/0000-0002-9103-6011","observed_orcids":["https://orcid.org/0000-0002-9103-6011"]},"institutions":[{"id":"https://openalex.org/I207623266","display_name":"Kao Corporation (Japan)","ror":"https://ror.org/016t1kc57","country_code":"JP","type":"company","lineage":["https://openalex.org/I207623266"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Masazumi Iwashita","raw_affiliation_strings":["R&D Strategy, R&D Strategy Promotion and Administration Center, R&D, Kao Corporation, Tokyo 131-8501, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"R&D Strategy, R&D Strategy Promotion and Administration Center, R&D, Kao Corporation, Tokyo 131-8501, Japan","institution_ids":["https://openalex.org/I207623266"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034502755","display_name":"Kohjiro Hashizume","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I207623266","display_name":"Kao Corporation (Japan)","ror":"https://ror.org/016t1kc57","country_code":"JP","type":"company","lineage":["https://openalex.org/I207623266"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kohjiro Hashizume","raw_affiliation_strings":["Biological Material Science Research Laboratories, Core Technology Research Center, R&D, Kao Corporation, Ichikai-machi 321-3497, Tochigi, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Material Science Research Laboratories, Core Technology Research Center, R&D, Kao Corporation, Ichikai-machi 321-3497, Tochigi, Japan","institution_ids":["https://openalex.org/I207623266"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103879626","display_name":"Kazunori Kato","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I158123994","display_name":"Toyo University","ror":"https://ror.org/059d6yn51","country_code":"JP","type":"education","lineage":["https://openalex.org/I158123994"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kazunori Kato","raw_affiliation_strings":["Department of Nutrition Sciences, Graduate School of Health and Sports Sciences, Toyo University, Tokyo 115-8650, Japan","Institute of Life Innovation Studies, Toyo University, Tokyo 115-8650, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Nutrition Sciences, Graduate School of Health and Sports Sciences, Toyo University, Tokyo 115-8650, Japan","institution_ids":["https://openalex.org/I158123994"]},{"raw_affiliation_string":"Institute of Life Innovation Studies, Toyo University, Tokyo 115-8650, Japan","institution_ids":["https://openalex.org/I158123994"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5047007335"],"corresponding_institution_ids":["https://openalex.org/I158123994"],"apc_list":{"value":2600,"currency":"CHF","value_usd":3137},"apc_paid":{"value":2600,"currency":"CHF","value_usd":3137},"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"14","issue":"11","first_page":"2591","last_page":"2591"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T14194","display_name":"Bioactive Compounds in Plants","score":0.9136000275611877,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T14194","display_name":"Bioactive Compounds in Plants","score":0.9136000275611877,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.046300001442432404,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.01590000092983246,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C2778401301","wikidata":"https://www.wikidata.org/wiki/Q2402963","display_name":"Nobiletin","level":4,"score":0.8040000200271606},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.7961000204086304},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.7843000292778015},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.6656000018119812},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6596999764442444},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.5565999746322632},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.42980000376701355},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.38449999690055847},{"id":"https://openalex.org/C25274449","wikidata":"https://www.wikidata.org/wiki/Q1805481","display_name":"Long-term potentiation","level":3,"score":0.36629998683929443},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.3564999997615814},{"id":"https://openalex.org/C197336794","wikidata":"https://www.wikidata.org/wiki/Q5161150","display_name":"Conjugate","level":2,"score":0.3427000045776367},{"id":"https://openalex.org/C53227056","wikidata":"https://www.wikidata.org/wiki/Q189152","display_name":"Viability assay","level":3,"score":0.3025999963283539},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.3003999888896942},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.28130000829696655}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.3390/biomedicines14112591","doi":"https://doi.org/10.3390/biomedicines14112591","is_oa":true,"landing_page_url":"https://doi.org/10.3390/biomedicines14112591","pdf_url":null,"source":{"id":"https://openalex.org/S2737005842","display_name":"Biomedicines","issn_l":"2227-9059","issn":["2227-9059"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310310987","host_organization_name":"Multidisciplinary Digital Publishing Institute","host_organization_lineage":["https://openalex.org/P4310310987"],"host_organization_lineage_names":["Multidisciplinary Digital Publishing Institute"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biomedicines","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.3390/biomedicines14112591","doi":"https://doi.org/10.3390/biomedicines14112591","is_oa":true,"landing_page_url":"https://doi.org/10.3390/biomedicines14112591","pdf_url":null,"source":{"id":"https://openalex.org/S2737005842","display_name":"Biomedicines","issn_l":"2227-9059","issn":["2227-9059"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310310987","host_organization_name":"Multidisciplinary Digital Publishing Institute","host_organization_lineage":["https://openalex.org/P4310310987"],"host_organization_lineage_names":["Multidisciplinary Digital Publishing Institute"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biomedicines","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":55,"referenced_works":["https://openalex.org/W1668489970","https://openalex.org/W1964743637","https://openalex.org/W1972090863","https://openalex.org/W1999356404","https://openalex.org/W2030619974","https://openalex.org/W2055318170","https://openalex.org/W2064839484","https://openalex.org/W2078386415","https://openalex.org/W2083709832","https://openalex.org/W2093580676","https://openalex.org/W2095110281","https://openalex.org/W2104182248","https://openalex.org/W2106513086","https://openalex.org/W2111473893","https://openalex.org/W2111708038","https://openalex.org/W2135079547","https://openalex.org/W2141913676","https://openalex.org/W2158741313","https://openalex.org/W2167847781","https://openalex.org/W2173303337","https://openalex.org/W2316506690","https://openalex.org/W2397751594","https://openalex.org/W2567894773","https://openalex.org/W2603616104","https://openalex.org/W2614353472","https://openalex.org/W2740434250","https://openalex.org/W2742314046","https://openalex.org/W2910361577","https://openalex.org/W2966824455","https://openalex.org/W2987630388","https://openalex.org/W2994610571","https://openalex.org/W3033457790","https://openalex.org/W3038010320","https://openalex.org/W3044497908","https://openalex.org/W3088588360","https://openalex.org/W3134422682","https://openalex.org/W3185886596","https://openalex.org/W3187322953","https://openalex.org/W3207608595","https://openalex.org/W4220847494","https://openalex.org/W4220898903","https://openalex.org/W4224266664","https://openalex.org/W4309737291","https://openalex.org/W4324150160","https://openalex.org/W4327968188","https://openalex.org/W4366764189","https://openalex.org/W4386484293","https://openalex.org/W4400748356","https://openalex.org/W4407881344","https://openalex.org/W4408241371","https://openalex.org/W4409978486","https://openalex.org/W4410729113","https://openalex.org/W4412495734","https://openalex.org/W7154899802","https://openalex.org/W7169513903"],"related_works":[],"abstract_inverted_index":{"Background:":[0],"Antibody\u2013drug":[1],"conjugates":[2],"(ADCs)":[3],"have":[4],"emerged":[5],"as":[6,275],"an":[7,89,193],"important":[8],"class":[9],"of":[10,31,59,93,102,114,155,191,259,267,279,286],"targeted":[11],"anticancer":[12],"therapeutics;":[13],"however,":[14],"their":[15,26],"efficacy":[16],"can":[17],"be":[18],"limited":[19],"by":[20],"intrinsic":[21],"or":[22],"acquired":[23],"resistance":[24],"to":[25,54,255],"cytotoxic":[27,57,189],"payloads.":[28],"Pharmacological":[29],"potentiation":[30,202],"payload":[32],"activity":[33,101,168,190,230],"may":[34,273],"therefore":[35],"provide":[36,265],"a":[37,45,108,181,239,270,276],"complementary":[38],"strategy":[39],"for":[40],"improving":[41],"ADC":[42,281],"efficacy.":[43],"Nobiletin,":[44],"polymethoxyflavone":[46],"derived":[47],"from":[48],"citrus":[49],"peel,":[50],"has":[51],"been":[52],"reported":[53],"enhance":[55],"the":[56,100,103,153,158,188,257,260],"effects":[58,113],"microtubule-targeting":[60],"agents,":[61],"but":[62],"its":[63,71,84,214],"poor":[64],"aqueous":[65],"solubility":[66],"and":[67,83,95,107,116,121,133,146,151,160,233],"low":[68],"bioavailability":[69],"restrict":[70],"in":[72,142,157,169,180,197,206,221,231,238,245],"vivo":[73],"application.":[74],"Objective:":[75],"In":[76,208],"this":[77,166,287],"study,":[78],"we":[79],"investigated":[80],"whether":[81],"nobiletin":[82,94,115,217],"bioavailability-enhanced":[85,271],"formulation,":[86],"Nob-MeHes":[87,117,163,226],"ASD,":[88],"amorphous":[90],"solid":[91],"dispersion":[92],"methyl":[96],"hesperidin,":[97],"could":[98],"potentiate":[99],"microtubule":[104],"inhibitor":[105],"DM1":[106],"DM1-containing":[109,280],"ADC.":[110],"Methods:":[111],"The":[112],"ASD":[118,164,227],"on":[119],"DM1-":[120],"\u03b1EpCAM-DM1-induced":[122],"cytotoxicity":[123,141,220],"were":[124,249],"evaluated":[125],"using":[126],"cell":[127,130],"viability":[128],"assays,":[129],"cycle":[131],"analysis,":[132],"mouse":[134],"xenograft":[135,183,241],"models.":[136],"Findings:":[137],"Nobiletin":[138,185],"enhanced":[139,187,234],"DM1-induced":[140],"DLD1":[143,223,240],"colorectal":[144],"cancer":[145,149,199],"BxPC-3":[147,182],"pancreatic":[148],"cells":[150,156],"increased":[152],"proportions":[154],"G2/M":[159],"Sub-G1":[161],"populations.":[162],"retained":[165],"potentiating":[167],"vitro":[170,232],"and,":[171],"when":[172],"combined":[173],"with":[174,216],"DM1,":[175],"significantly":[176],"suppressed":[177],"tumor":[178,235],"growth":[179,236],"model.":[184,242],"also":[186,204],"\u03b1EpCAM-DM1,":[192],"EpCAM-targeting":[194],"DM1-conjugated":[195],"ADC,":[196],"EpCAM-positive":[198],"cells,":[200],"although":[201],"was":[203],"observed":[205],"HUVEC.":[207],"contrast,":[209],"neither":[210],"\u03b1EpCAM-DM1":[211,229],"alone":[212],"nor":[213],"combination":[215,288],"showed":[218],"appreciable":[219],"EpCAM-knockout":[222],"cells.":[224],"Furthermore,":[225],"potentiated":[228],"suppression":[237],"Although":[243],"changes":[244],"serum":[246],"biochemical":[247],"parameters":[248],"observed,":[250],"further":[251,284],"studies":[252],"are":[253],"required":[254],"establish":[256],"safety":[258],"combination.":[261],"Conclusions:":[262],"These":[263],"findings":[264],"proof":[266],"concept":[268],"that":[269],"phytochemical":[272],"serve":[274],"pharmacological":[277],"potentiator":[278],"therapy,":[282],"supporting":[283],"investigation":[285],"strategy.":[289]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-11T00:00:00"}